Sort
15,273 grants matching “antimicrobial resistance”
Isolating novel fungi for antibiotic discovery
$999,832Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2011 · AI
Lab-on-a-Film Multiplexed Test for Respiratory Mycobacterial Infections
$999,739Christopher Gerard Cooney · Akonni Biosystems, Inc. · R44 · FY2022 · AI
Aminoglycosides with reduced ototoxicity
$999,707Dev Priya Arya · Nubad, Llc · R42 · FY2024 · AI
Aminoglycosides with reduced ototoxicity
$999,707Dev Priya Arya · Nubad, Llc · R42 · FY2023 · AI
Drug Discovery from Slow Growing and Rare Microbial Species
$999,651Amy Lynn Spoering · Novobiotic Pharmaceuticals, Llc · R44 · FY2013 · AI
Development of a Dual-Targeting ClpP Activating Antibiotic
$999,619Michael Lafleur · Arietis · R44 · FY2024 · AI
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** AGRICULTURE ACCOUNTS FOR MORE THAN 80% OF THE NATION'S WATER CONSUMPTION. AS GLOBAL POPULATIONS GROW, MORE WATER WILL BE REQUIRED FOR AGRICULTURAL PRODUCTION. RECLAIMED WATER IS HIGHLY TREATED WASTEWATER THAT CAN BE REUSED FOR VARIOUS PURPOSES, INCLUDING AGRICULTURE AND LANDSCAPE IRRIGATION. USING RECLAIMED WATER FOR AGRICULTURE WILL FREE UP DRINKING WATER AND INCREASE OUR WATER SUPPLY RELIABILITY.CONVENTIONAL MUNICIPAL WASTEWATER TREATMENT PLANTS PRODUCE RECLAIMED WATER BY TREATING WASTEWATER. THESE TREATMENT PLANTS RECEIVE WASTEWATER CONTAINING VARIOUS POLLUTANTS, INCLUDING ANTIBIOTICS AND MICROORGANISMS. WHEN THESE MICROORGANISMS ARE EXPOSED TO ANTIBIOTICS, THEY CAN EVOLVE ANTIMICROBIAL RESISTANCE LEADING TO AN INCREASE IN ANTIBIOTIC-RESISTANCE GENES (ARGS), ANTIBIOTIC-RESISTANT BACTERIA (ARBS), AND MOBILE GENETIC ELEMENTS (MGES). ANTIBIOTICS, ARGS, ARBS, AND MGES, ARE COLLECTIVELY KNOWN AS ANTIBIOTIC RESISTANCE DETERMINANTS (ARDS). WASTEWATER TREATMENT PLANTS DO NOT ADEQUATELYREMOVE ARDS; THEREFORE, SUBSEQUENT POLISHING TO REMOVE THE ARDS FROM TREATED MUNICIPAL WASTEWATER IS DESIRABLE TO CURTAIL ANTIBIOTIC RESISTANCE IN AGRICULTURAL FIELDS IRRIGATED WITH RECLAIMED WATER AND THE ENVIRONMENT.OUR TEAM HAS DEVELOPED A NOVEL BIOCHAR-BASED LABORATORY-SCALE POLISHING SYSTEM THAT EFFICIENTLY REMOVES ANTIBIOTICS FROM RECLAIMED WATER. BIOCHARS ARE ORGANIC MATTER BURNT IN AN OXYGEN-STARVED ENVIRONMENT. THEY HAVE HIGH ADSORPTION POTENTIAL FOR ORGANIC COMPOUNDS AND CAN BE USED AS A COST-EFFECTIVE MATERIAL FOR FILTRATION. BIOCHARS PREPARED (ENGINEERED) FROM VARIOUS FEEDSTOCKS,PYROLYSIS TEMPERATURES, AND POST-PYROLYSIS MODIFICATIONS, HAVE DIFFERENT ANTIBIOTIC ADSORPTION PROPERTIES AND PHYSICOCHEMICAL CHARACTERISTICS. BASED ON THIS KNOWLEDGE, A BIOCHAR TYPE CAN BE DESIGNED FOR THE SPECIFIC ANTIBIOTIC COMPOUNDS FOUND INRECLAIMED WATER.IN THE CURRENT STUDY, WE PROPOSE DEVELOPING A LARGE-SCALE, HIGHLY-EFFECTIVE ANTIMICROBIAL RESISTANCE MITIGATION SYSTEM THAT INCORPORATES ENGINEERED BIOCHAR ADSORBENTS TAILORED TO SPECIFIC CONTAMINANTS IN RECLAIMED WATER. WE WILL ASSESS THE SYSTEM'S PERFORMANCE REGARDING REMOVING ARDS FROM TARGET RECLAIMED WATER. MOREOVER, WE WILL USE SUBSEQUENT POTTED EDIBLE PLANTS (E.G., SPINACH AND RADISH) GROWN UNDER GREENHOUSE CONDITIONS TO STUDY THE EFFECT OF RECLAIMED WATER ON ARD DISSEMINATION AND LINK TREATMENT SYSTEM EFFICACY TO ECOLOGICAL PARAMETERS INDICATIVE OF ANTIMICROBIAL MITIGATION. LASTLY, A PILOT-SCALE SYSTEM WILL BE DEVELOPED FOR COUPLING WITH A CONVENTIONAL FIELD-SCALE CROP IRRIGATION SYSTEM. THE PILOT BIOCHAR-BASED POLISHING SYSTEM WILL BE ASSESSED FOR PERFORMANCE IN REDUCING ANTIMICROBIAL RESISTANCE DISSEMINATION IN SOILS AND PLANTS IRRIGATED WITH RECLAIMED WATER. EXTENSION WORKSHOPS FOR FARMERS AND STAKEHOLDERS WILL BE CONDUCTED ON THE RISKS OF ANTIMICROBIAL RESISTANCE DISSEMINATION IN AGRICULTURE AND THEIR MITIGATION WITH OUR BIOCHAR-BASED POLISHING SYSTEMS. AT WORKSHOPS, WE WILL DEMONSTRATE THE BIOCHAR-BASED POL,ISHING SYSTEM FOR RECLAIMED WATER AND OUR FINDINGS ON REDUCING ANTIMICROBIAL RESISTANCE IN SOIL AND CROPS IRRIGATED WITH POLISHED RECLAIMED WATER. RISK ASSESSMENTS WILL ALSO BE CONDUCTED TO QUANTIFY THE EXTENT TO WHICH THE POLISHING SYSTEM REDUCES HUMAN EXPOSURE TO ANTIMICROBIAL RESISTANCE VIA THE FOOD CHAIN. THE WORK WILL ASSIST IN CURTAILING ANTIMICROBIAL RESISTANCE DISSEMINATION IN AGRICULTURE TO PROTECTHUMAN HEALTH AND THE ENVIRONMENT.
$999,618Regents Of The University Of California At Riverside · · FY2023 · National Institute of Food and Agriculture
Isolating novel actinomycetes for antibiotic discovery
$999,586Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2011 · AI
Preclinical development of teixobactin, a new antibiotic
$999,567Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R44 · FY2020 · AI
Development of peptide nucleic acid antibiotics
$999,557Dev Priya Arya · Nubad, Llc · R42 · FY2023 · AI
A Multiplexed Diagnostic Immunoassay for Clostridium Difficile and Antibiotic-Associated Diarrhea
$999,517Kerry Oliver · Radix Biosolutions, Ltd · N44 · FY2015 · AI
Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia
$999,509Christie G. Brouillette · University Of Alabama At Birmingham · U01 · FY2010 · AI
Collaborative Research: FEC: Establishing Infrastructure for AI-Driven Discovery of Small Molecules to Combat Antibiotic Resistance, Biofilms, and Aflatoxin Contamination
$999,470Boo Shan Tseng · University Of Nevada Las Vegas · · FY2025 · O/D
Isolating novel actinomycetes for antibiotic discovery
$999,461Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2010 · AI
Dual Function Catheter to Prevent Thrombus and Infection
$999,440Jennifer Ann Neff · Allvivo Vascular, Inc. · R44 · FY2011 · DK
Coordinate Regulation of Virulence in Vibrio Cholerae
$999,436John J Mekalanos · Harvard Medical School · R37 · FY2025 · AI
Lab-on-a-Film Multiplexed Test for Respiratory Mycobacterial Infections
$999,394Christopher Gerard Cooney · Akonni Biosystems, Inc. · R44 · FY2023 · AI
Isolating novel fungi for antibiotic discovery
$999,356Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2010 · AI
Isolating novel fungi for antibiotic discovery
$999,313Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2012 · AI
Isolating novel actinomycetes for antibiotic discovery
$999,308Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2009 · AI
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy
$999,300Frank H. Ebetino · Biovinc, Llc · R44 · FY2020 · AI
Therapeutic Development of Antimicrobial Biomimetics
$999,095Richard W Scott · Polymedix, Inc, · R44 · FY2006 · AI
Preclinical development of teixobactin, a new antibiotic
$999,040Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R44 · FY2018 · AI
Therapeutic Development of Antimicrobial Biomimetics
$998,970Richard W Scott · Polymedix, Inc, · R44 · FY2007 · AI
Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing
$998,700Paul Rhodes · Specific Diagnostics, Inc. · R44 · FY2020 · AI